comprehensive -WSS

comprehensive

author：entertainment 2025-09-28 17:43:42 - browse：24517

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Physicians aren't 'burning out.' They're suffering from moral injury

WSS

STAT Virtual Event: How to Increase Diversity in Clinical Trials

2 officers injured in shooting in Orlando, police say

Why do women spend more than men on medical expenses?

Cigna to pay $172 million to settle Medicare Advantage fraud probe

How to ethically and practically extend health care to all

Address the ethical violations that led to 'Three Identical Strangers'

entertainment

comprehensive

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

How I helped Pfizer think through the ethics of Viagra

Bright Health sells Medicare Advantage business to Molina

How to ethically and practically extend health care to all

Tori Bowie and the unacceptable rates of Black maternal death

Researchers use wearables data and AI to predict preterm birth risk

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Shingles, which affected Dianne Feinstein, is on the rise

Guidelines to prevent youth baseball injuries need more muscle

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

focus

H.R. 3 is the wrong path to lower drug costs

Health tech startups drop sharply from 2021 highs

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Intercept Pharmaceuticals sells itself for less than $1 billion

Mindstrong's demise and the future of mental health care

Senator probes 340B programs at Cleveland Clinic, Bon Secours

focus

knowledge

explore

knowledge